Status: Recruiting
Evaluation of Safety, Pharmacokinetics and Pharmacodynamics of Arnovie101, an mRNA-LNP-Based In Vivo CAR-T Therapy, for the Treatment of B Cell-Mediated Autoimmune Diseases (SLE and AIHA)
This is an open lable and single arm study designed to evaluate the safety, PK and PD of Arnovie101 in B cell-mediated Autoimmune Disease
Participants needed: 5
Trial details
Phase: Early Phase 1Age: 18-60Biological sex: AllType: InterventionalSponsor: Circunited BioPharma (Shenzhen) Co., Ltd.Updated: Jun 5, 2026Locations: 1
Eligibility criteria
Ability to voluntarily sign informed consent, including compliance with the requ... [+3]
Presence of an unresected thymoma. [+18]